FDA Panel Nixes Bevacizumab for Breast Cancer

posted on Jul 20 by MedPage Today OB/Gyn in the Uncategorized category (MedPage Today) -- GAITHERSBURG, Md. -- An advisory panel has voted 12 to 1 to recommend that the FDA remove the advanced breast cancer indication from bevacizumab (Avastin), after two large clinical trials failed to demonstrate a clinically meaningful benefit of the drug, which carries serious side effects.